Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin dose requirements in obese parturients undergoing cesarean section
ChiCTR2200059582Phase 4Not yet recruiting
- Sponsor
- Jiaxing Maternity and Child Health Care Hospital
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of oxytocin in obesity and uterine atony (4 arms), sponsored by Jiaxing Maternity and Child Health Care Hospital. Primary endpoint: Oxytocin dosage during cesarean section. Planned start May 2022; status: not yet recruiting.
02
Drugs
oxytocin
03
Conditions
obesityuterine atony
Beyond the preview
Go deeper on ChiCTR2200059582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059582.